Skip to main content
SpringerLink
Log in

Clozapine oral suspension (Versacloz™): a guide to its use in the USA

  • ADIS DRUG CLINICAL Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Clozapine, an atypical antipsychotic, has recently become available in the USA in the form of an oral suspension (Versacloz™). The oral suspension formulation has several potential advantages over traditional tablet formulations. The efficacy of clozapine in the treatment of treatment-resistant schizophrenia, and in reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder, is well-established. Although its use has been limited by its association with serious hematological toxicity, it is considered the antipsychotic of choice in patients with treatment-resistant schizophrenia, and is also of benefit in reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wagstaff AJ, Bryson HM. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs. 1995;4(5):370–400.

    Article  CAS  Google Scholar 

  2. Wagstaff AJ, Perry CM. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS Drugs. 2003;17(4):273–80.

    Article  CAS  PubMed  Google Scholar 

  3. Kerwin R. When should clozapine be initiated in schizophrenia? Some arguments for and against earlier use of clozapine. CNS Drugs. 2007;21(4):267–78.

    Article  CAS  PubMed  Google Scholar 

  4. Fakra E, Azorin JM. Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother. 2012;13(13):1923–35.

    Article  CAS  PubMed  Google Scholar 

  5. Versacloz (clozapine) oral suspension: US prescribing information. Palo Alto: Jazz Pharmaceuticals, Inc., 2013.

  6. Englisch S, Zink M. Treatment-resistant schizophrenia: evidence-based strategies. Mens Sana Monogr. 2012;10:20–32.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012;6(3):134–44.

    Article  PubMed  Google Scholar 

  8. Raja M. Clozapine safety, 35 years later. Curr Drug Saf. 2011;6(3):164–84.

    Article  CAS  PubMed  Google Scholar 

  9. Hill M, Feudenreich O. Clozapine: key discussion points for prescribers. Clin Schizophr Relat Psychoses. 2013;6(4):177–85.

    Article  PubMed  Google Scholar 

  10. Kreyenbuhl J, Buchanan RW, Dicerson FB, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94–103.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Lehman AF, Lieberman JA, DIxon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. American Psychiatric Association; Steering Committee on Practice Guidelines. Am J Psychiatry. 2004;161(2 Suppl):1–56.

    Google Scholar 

  12. Mamo DC. Managing suicidality in schizophrenia. Can J Psychiatry. 2007;52(6 Suppl 1):59S–70S.

    PubMed  Google Scholar 

  13. Wasserman D, Rihmer Z, Rujescu D, et al. The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry. 2012;27(2):129–41.

    Article  CAS  PubMed  Google Scholar 

  14. Sinyor M, Remington G. Is psychiatry ignoring suicide? The case for clozapine. J Clin Psychopharmacol. 2012;32(3):307–8.

    Article  PubMed  Google Scholar 

  15. Kasckow J, Felmet K, Zisook S. Managing suicide risk in patients with schizophrenia. CNS Drugs. 2011;25(2):129–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Foster TJ. Suicide prevention as a prerequisite for recovery from severe mental illness. Int J Psychiatry Med. 2013;46(1):15–25.

    Article  PubMed  Google Scholar 

  17. Glue P, Gale C, Menkes DB, et al. Evaluation of bioequivalence between clozapine suspension and tablet formulations: a multiple-dose, fed and fasted study. Clin Drug Investig. 2012;32(11):723–7.

    Article  CAS  PubMed  Google Scholar 

  18. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (March 2014). London: BMJ Group and the Royal Pharmaceutical Society; 2014.

  19. Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):996–1008.

    Article  CAS  PubMed  Google Scholar 

  20. Kelleher JP, Centorrino F, Albert MJ. Advances in atypical antipsychotics for the treatment of schizophrenia. CNS Drugs. 2002;16(4):249–61.

    Article  CAS  PubMed  Google Scholar 

  21. Mcilwain ME, Harrison J, Wheeler AJ, et al. Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatric Dis Treat. 2011;7:135–49.

    CAS  Google Scholar 

  22. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):78–96.

    Article  Google Scholar 

  23. Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother. 2012;13(11):1545–73.

    Article  CAS  PubMed  Google Scholar 

  24. Tandon R, Belmaker Rh, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1–3):20–38.

    Article  PubMed  Google Scholar 

  25. Souza JS, Kayo M, Tassell I, et al. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr. 2013;18(2):82–9.

    Article  PubMed  Google Scholar 

  26. Attard A, Taylor DM. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? CNS Drugs. 2012;26(6):491–508.

    Article  CAS  PubMed  Google Scholar 

  27. Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007;21(1):25–35.

    Article  CAS  PubMed  Google Scholar 

  28. Taylor D, Shapland L, Laverick G, et al. Clozapine: a survey of patient perceptions. Psychiatr Bull. 2000;24:450–2.

    Article  Google Scholar 

  29. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91.

    Article  CAS  PubMed  Google Scholar 

  30. Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol. 1998;21(4):245–5.

    Google Scholar 

  31. Ciapparelli A, Dell’Osso L, Pini S, et al. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry. 2000;61(5):329–34.

    Google Scholar 

  32. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995;152(2):183–90.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: M. Hahn, Vitos Rheingau, Eltville, Germany; E. Obarcanin, Sarajevo, Bosnia and Herzegovina; S. Saluja, Consultant in Internal Medicine, Saran Ashram, Agra, India.

Disclosure

The preparation of this article was not supported by any external funding. K.A. Lyseng-Williamson is a salaried employee of Adis/Springer. During the review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A. Clozapine oral suspension (Versacloz™): a guide to its use in the USA. Drugs Ther Perspect 30, 193–199 (2014). https://doi.org/10.1007/s40267-014-0124-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-014-0124-6

Keywords

Search

Navigation